Gold prices steady ahead of Fed decision; weekly weakness noted
Adam David Sachs, CEO of Vicarious Surgical Inc. (NYSE:RBOT), recently sold shares in the company, according to a Form 4 filing with the Securities and Exchange Commission. The stock, which InvestingPro data shows has gained over 40% in the past six months despite a recent 20% weekly decline, appears fairly valued based on current analysis. The transaction, dated March 21, involved the sale of 161 shares of Class A Common Stock at an average price of $7.9196 per share, totaling $1,275.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units originally granted on November 23, 2021. Following this transaction, Sachs retains ownership of 52,003 shares in the company.
In other recent news, Vicarious Surgical Inc. reported its financial results for the fourth quarter of 2024, highlighting a significant reduction in operating expenses by 17% year-over-year. The company reported a fourth-quarter adjusted EPS of -$2.43, better than the expected -$2.69 by analysts. Despite these improvements, Vicarious Surgical disclosed zero revenue for the quarter. The company anticipates a cash burn of approximately $50 million in 2025, similar to the previous year. Meanwhile, Piper Sandler adjusted its outlook on Vicarious Surgical, lowering the price target to $8.50 from $10.50 but maintaining a Neutral rating, citing recent developments and the company’s financial guidance. BTIG also maintained a Neutral rating following the earnings report. Additionally, Vicarious Surgical announced the successful integration of its Version 1.0 surgical robotic system, marking a pivotal step towards achieving its clinical and market goals. However, supply chain issues have delayed the timeline for first-in-human cases to late 2025, a shift from the previously anticipated schedule.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.